Anna Baran
Anna Baran is an equity analyst on the healthcare team for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc.
Before joining Morningstar in 2016, Baran completed a research project in oncology at the Feinberg School of Medicine and another research thesis in neurobiology at Northwestern University. Before moving to her current role in February 2018, she was on the global and managed portfolios service teams at Morningstar.
Baran holds a bachelor’s degree in economics and biological sciences from Northwestern University. She is also a Level II candidate in the Chartered Financial Analyst® program.
Latest
All Eyes on BioNTech's COVID-19 Vaccine
Jun 26, 2020
An Undervalued but High Uncertainty Biotech Firm
Oct 9, 2019
An Undervalued but High Uncertainty Biotech Firm
Oct 9, 2019
Intercept Looks to Be First in Lucrative Market
Jul 19, 2019
Alexion's Rare-Disease Reign Not Over
Mar 6, 2019
CROs Poised to Benefit From Biopharma Outsourcing
Jan 11, 2019